About US
Contact us
-
CFDA issues announcement on further standardizing naming of health foodThe revised Food Safety Law of the People's Republic of China will come into effect as of October 1, 2015. In accordance with the requirement of strict supervision to health food, China Food and Drug2015/8/28
-
The FDA has spoken on biosimilar names. But will its hybrid proposal work?After much industry lobbying and public debate, theFDAhas proposed a system for naming biosimilar drugs. It's a sort of hybrid of the generic name on one hand and the unique brand name on the other. A2015/8/28
-
On the heels of big production news, Novo Nordisk snaps up two diabetes drug developersNovo Nordisk ($NVO) has had a big week. After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker no2015/8/28
-
Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitorMedivation ($MDVN) made a name for itself withXtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers i2015/8/27
-
UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk ($NVO) will spend about $1.2 billion on its firstAPIplant in the U.S., a project that is expected to bring 7002015/8/27
-
Stock slide makes biopharma deals more enticing for Gilead (and everyone else)Analysts and investors may have been ready for Gilead Sciences ($GILD) to make an M&A move before now. But with stocks on a slide, they might be glad Gilead hasn't yet. As theWall Street Journalp2015/8/26
-
Teva bows out of voting on Mylan's proposed deal for PerrigoFriday, Mylan's ($MYL) shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo ($PRGO). But Teva ($TEVA) won't be among them, despite the fact that it built up2015/8/26
-
J&J uses share-the-wisdom approach to spread the word on PrezcobixJohnson & Johnson ($JNJ) is trying a new tack on the old "talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and2015/8/25
-
Allergan recalls eye drugs after patients complain of particles, blurred visionSince Allergan ($AGN) andActavisjoined hands to become a new-look Allergan, the company has already had to recall a product from the Actavis side. Now, it's recalling some from the Allergan side, putt2015/8/25
-
Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market m2015/8/24